Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SPECT CT Clear all
Completed Phase 2 Interventional Results available

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT Imaging

NCT02773238
View directory record Official record
Conditions
Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Interventions
Computed Tomography, Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Positron Emission Tomography, Radiation Therapy, Single Photon Emission Computed Tomography, Technetium Tc-99m Albumin Aggregated, Technetium Tc-99m Sulfur Colloid
Procedure · Radiation · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Sep 7, 2026, 4:53 AM EDT
Enrolling by invitation Not applicable Interventional

Pilot Evaluation of the StarGuide Next Generation SPECT/CT System

NCT07272161
View directory record Official record
Conditions
Nuclear Medicine
Interventions
StarGuide NextGen SPECT/CT system
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Brain Imaging and Treatment Studies of the Night Eating Syndrome

NCT01401595
View directory record Official record
Conditions
Night Eating Syndrome
Interventions
escitalopram oxalate
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 7, 2026, 4:53 AM EDT
Recruiting Phase 2Phase 3 Interventional

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

NCT04333537
View directory record Official record
Conditions
Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Gingival Squamous Cell Carcinoma, Hard Palate Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma, Stage I Lip and Oral Cavity Cancer AJCC v8, Stage II Lip and Oral Cavity Cancer AJCC v8, Tongue Squamous Cell Carcinoma, Upper Alveolar Ridge Squamous Cell Carcinoma
Interventions
Chest Radiography, Computed Tomography, Fludeoxyglucose F-18, Imaging Agent, Neck Dissection, Planar Imaging, Positron Emission Tomography, Questionnaire Administration, Sentinel Lymph Node Biopsy, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2036
U.S. locations
106
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

NCT05591092
View directory record Official record
Conditions
Thyroid Gland Follicular Carcinoma
Interventions
Computed Tomography, Iodine I-123, Planar Imaging, Single Photon Emission Computed Tomography
Procedure · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects

NCT00470925
View directory record Official record
Conditions
Depression
Interventions
123-I MZINT injection and SPECT imaging
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 7, 2026, 4:53 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety of Escalating Doses of Tilmanocept by IV Injection and SPECT Imaging in Subjects With and Without RA

NCT02865434
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Tc99m-tilmanocept, SPECT Imaging (60 Minutes post-injection), SPECT Imaging (180 Minutes post-injection), Whole body planar SPECT imaging (15 Minutes post-injection), Whole body planar SPECT imaging (60 Minutes post-injection), Whole body planar SPECT imaging (180 Minutes post-injection), Whole body planar SPECT imaging (18-20 Hours post-injection), Blood Collection for PK Testing (15 Mins Before Injection), Blood Collection for PK Testing (after injection), Blood Collection for PK Testing (15 minutes post injection), Blood Collection for PK Testing (60 minutes post injection), Blood Collection for PK Testing (180 minutes post injection), Blood Collection for PK Testing (18-20 hours post injection), Planar Image with both Hands in Field of View
Drug · Procedure
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Kettering, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Sep 7, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

NCT06216249
View directory record Official record
Conditions
Prostate Carcinoma, Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, PSMA PET Scan, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Terminated Early Phase 1 Interventional

4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy

NCT01034514
View directory record Official record
Conditions
Lung Cancer
Interventions
Real-time Position Management system, Discovery ST multislice PET/CT scanner, Infinia Hawkeye SPECT/CT gamma camera, Pinnacle3 treatment planning system, SKYLight nuclear camera, DTPA, TECHNETIUM TC 99M MAA
Device · Drug
Lead sponsor
Billy W. Loo Jr.
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 7, 2017 · Synced Sep 7, 2026, 4:53 AM EDT
Not yet recruiting Phase 2 Interventional

Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

NCT07650240
View directory record Official record
Conditions
Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8, Castration-Sensitive Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma, Adenocarcinoma of the Prostate, Localized Prostate Carcinoma, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma, Advanced Prostate Cancer, Advanced Prostate Adenocarcinoma
Interventions
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate, Lutetium Lu 177 Vipivotide Tetraxetan, Prednisone, PSMA PET-CT Scan, Quality-of-Life Assessment, Single Photon Emission Computed Tomography
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Completed No phase listed Observational Results available

Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases

NCT01743040
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
CADence
Diagnostic Test
Lead sponsor
AUM Cardiovascular, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 7, 2026, 4:53 AM EDT
Withdrawn No phase listed Observational

Registry for CARDIAC PERFUSION CT

NCT01346605
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
MDDX LLC
Industry
Eligibility
35 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 10, 2012 · Synced Sep 7, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Lung Imaging of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)

NCT02978144
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
AxV-128/Tc
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 7, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dosimetry of Tc-99m-Tilmanocept

NCT05241522
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
Tc-99m-Tilmanocept
Diagnostic Test
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Mechanisms of Resistance to PSMA Radioligand Therapy

NCT05435495
View directory record Official record
Conditions
Prostate Cancer
Interventions
Single-photon emission computed tomography, Blood Draw, Tumor Biopsy
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Completed No phase listed Observational

DatScan With Prototype Collimator

NCT02455219
View directory record Official record
Conditions
Parkinson Disease
Interventions
Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator
Device
Lead sponsor
University of Minnesota
Other
Eligibility
50 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 7, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy

NCT04904120
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IV, Melanoma, Uveal, Melanoma, Mucosal
Interventions
[203Pb]VMT01, [68Ga]VMT02
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 89 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 7, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

NCT03011320
View directory record Official record
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Sep 7, 2026, 4:53 AM EDT
Terminated Not applicable Interventional Results available

Randomized Evaluation of Patients With Stable Angina Comparing Diagnostic Examinations

NCT01262625
View directory record Official record
Conditions
Chest Pain, Stable Angina Pectoris, CCS Class I to III, Angina Equivalent, Coronary Artery Disease
Interventions
CCTA, SPECT MPI/ICA
Device
Lead sponsor
American College of Radiology
Other
Eligibility
40 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Decatur, Georgia • Detroit, Michigan • Salem, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 7, 2026, 4:53 AM EDT
Completed No phase listed Observational

Acute Chest Pain Imaging in the ED With the Combine CCTA and CT Perfusion

NCT02538861
View directory record Official record
Conditions
Chest Pain
Interventions
SPECT Imaging Test at Baptist hospital, CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital, SPECT Imaging Test at West Kendall Baptist Hospital
Diagnostic Test
Lead sponsor
Baptist Health South Florida
Other
Eligibility
35 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 7, 2026, 4:53 AM EDT
Not listed Phase 1 Interventional

The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer

NCT01159405
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiolabeled (99mTc) GP (Glycopeptide)
Radiation
Lead sponsor
SeeCure LLC
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Sep 7, 2026, 4:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma

NCT05655312
View directory record Official record
Conditions
Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV, Melanoma Stage III
Interventions
[203Pb]VMT01, [212Pb]VMT01, Nivolumab
Drug
Lead sponsor
Perspective Therapeutics
Industry
Eligibility
18 Years to 90 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Orange, California • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 7, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Inflammation and Cardiovascular Health in Women

NCT04224181
View directory record Official record
Conditions
HIV/AIDS, Myocardial Infarction
Interventions
Cardiac PET, 99mTc-tilmanocept SPECT/CT, Contrast Enhanced Coronary and Aortic Computed Tomography Angiography
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 79 Years · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 19, 2024 · Synced Sep 7, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

NCT06288113
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide, Lutetium Lu 177 Vipivotide Tetraxetan, Positron Emission Tomography, Questionnaire Administration, Single Photon Emission Computed Tomography
Procedure · Other · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 7, 2026, 4:53 AM EDT